PURE Bioscience, Inc.
PURE
$0.08
$0.0228.21%
OTC PK
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.05% | 13.55% | 27.34% | 61.18% | 11.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.05% | 13.55% | 27.34% | 61.18% | 11.34% |
| Cost of Revenue | 13.94% | 25.61% | 11.69% | 48.74% | 13.66% |
| Gross Profit | -4.95% | 4.85% | 38.46% | 70.18% | 9.69% |
| SG&A Expenses | -8.76% | -2.76% | -15.66% | -13.49% | -22.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.74% | 0.99% | -8.11% | -1.17% | -14.55% |
| Operating Income | 11.30% | 5.79% | 39.55% | 47.42% | 28.52% |
| Income Before Tax | -7.59% | 1.63% | 32.66% | 56.08% | 32.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.59% | 1.63% | 32.66% | 56.08% | 32.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.59% | 1.63% | 32.66% | 56.08% | 32.32% |
| EBIT | 11.30% | 5.79% | 39.55% | 47.42% | 28.52% |
| EBITDA | 11.15% | 5.87% | 35.93% | 44.09% | 25.35% |
| EPS Basic | -7.69% | 1.41% | 33.87% | 55.88% | 32.47% |
| Normalized Basic EPS | 5.41% | 2.22% | 31.58% | 51.28% | 22.92% |
| EPS Diluted | -7.69% | 1.41% | 33.87% | 55.88% | 32.47% |
| Normalized Diluted EPS | 5.41% | 2.22% | 31.58% | 51.28% | 22.92% |
| Average Basic Shares Outstanding | -0.92% | 0.03% | 0.03% | 0.02% | 0.00% |
| Average Diluted Shares Outstanding | -0.92% | 0.03% | 0.03% | 0.02% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |